Drug intelligence / Profile preview

miR-145 lentiviral vector

Development stage
Preclinical
Modality
Lentiviral Vectors → Retroviral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Direct Injection (intra-tumoral, Intravenous, In Vivo Experimental), Transduction Of Cultured Cells
01

Overview

A **miR-145 lentiviral vector** is a gene therapy research tool and experimental pharmaceutical based on a recombinant lentiviral vector engineered to express the microRNA miR-145. This construct is used to deliver and induce stable overexpression of miR-145 in target cells for preclinical or laboratory investigation. miR-145 functions as a tumor suppressor microRNA and its overexpression via lentiviral delivery has been shown to inhibit cancer cell proliferation, migration, invasion, EMT (epithelial-mesenchymal transition), stemness of cancer stem cells, and to induce apoptosis across various tumor models including liver cancer stem cells and esophageal carcinoma cells[1][2]. In metabolic disease models, lentiviral miR-145 reduces inflammatory pathways, macrophage infiltration, and improves glucose metabolism, partly by targeting OPG, KLF5, and downregulating NF-κB activation[3]. In liver cancer, it targets COL4A3 and modulates the Wnt/β-catenin and autophagy pathways[1]. The miR-145 lentiviral vector is most often used in research settings for both in vitro and in vivo studies and is not approved for clinical use.

Other names
miR-145 lentivirusmiR145 lentivirusmiR 145 lentiviruslv-miR-145lv-miR145lv-miR 145miR-145-5p lentiviral vectormiR145-5p lentiviral vectormiR 145-5p lentiviral vectormiR-145-5p-loaded lentivirusmiR145-5p-loaded lentivirusmiR 145-5p-loaded lentivirus
02

Targets

OPG (Osteoprotegerin)Collagen type IV alpha 3 chain mRNA

Beyond the preview

Go deeper on miR-145 lentiviral vector.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-145 lentiviral vector.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call